News

April 28, 2025

HistoSonics’ Histotripsy System Demonstrates 90% Local Tumor Control at 12 Months in #HOPE4LIVER Trials

HistoSonics, the developer of the Edison Histotripsy System, announced today 12-month follow-up clinical data from its prospective #HOPE4LIVER trials, designed […]
December 19, 2024

HistoSonics non-invasive tumor destruction featured in Reuters Global Health Documentary Series

HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, released today a short documentary as part […]
December 16, 2024

HistoSonics Edison® Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial

HistoSonics, the developer and manufacturer of the Edison Histotripsy System, announced today the first patients with pancreatic tumors were successfully […]
November 18, 2024

HistoSonics® Enrolls First Patients in Company’s Novel BOOMBOX Master Study

HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the first patients were enrolled in their novel […]
October 28, 2024

HistoSonics® Awarded Exclusive Contract with Veterans Affairs for Tumor Destroying Histotripsy Systems

HistoSonics, the developer and manufacturer of the Edison Histotripsy System, announced today they have been awarded an exclusive contract to […]
September 3, 2024

HistoSonics® Publishes Results of its Pivotal #HOPE4LIVER Trials

HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the publication of the company’s pivotal clinical trials […]
1 2 3 7

Last updated on April 28, 2025

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on April 30, 2025
X New Twitter Logo
© 2019-2025 HistoSonics®. All rights reserved.
HistoSonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.